Christine Brideau's Biography

Christine Brideau, Vice President of In Vitro Biology, WuXi

Christine Brideau joined WuXi AppTec in January 2014 and currently heads the In Vitro Biology groups in the US and Shanghai, China. She is responsible for in vitro assay development, screening and the characterization of small molecules in support of Drug Discovery services. She leads a team of biochemists, cell biologists and automation specialists.

Christine received her Bachelor of Science degree in Cell & Molecular Biology at Concordia University, Montreal, in 1986. She then studied Atherosclerosis & Diabetes research at McGill University. She joined the Pharmacology department at Merck Frosst Center for Therapeutic Research in Kirkland, Canada in 1990. Christine has over 24 years of drug discovery experience. Her experience spans from in vivo pharmacology to high throughput screening (HTS) in various disease areas such as inflammation, asthma, metabolic disorders, hypertension and infectious diseases. She developed critical target engagement assays in whole blood and primary cells leading to the discovery and the market approval of several coxib drugs for human (Arcoxia®) and animal health (Previcox®, Equioxx®). In 1998, she established a state of the art high throughput screening facility and implemented automated compound management and screening systems at the Merck Frosst Center for Therapeutic Research in Montreal. She relocated to Merck in the US to build and lead the In Vitro Pharmacology group at Kenilworth, NJ in 2010. She has co-authored over 40 peer-reviewed publications in areas of pharmacology, assay development, data analysis of screening data, automation and compound management. As a recognized expert in the area of High Throughput Screening, she served as an ad hoc reviewer for the Journal of Biomolecular Sciences, the NIH Molecular Libraries Program study sections and the Translational Panel of the Ontario Institute for Cancer Research.